More about

Interstitial Lung Disease

News
November 12, 2022
3 min read
Save

Risk score predicts interstitial lung disease risk at first systemic sclerosis diagnosis

Risk score predicts interstitial lung disease risk at first systemic sclerosis diagnosis

PHILADELPHIA — A novel risk score accurately predicted interstitial lung disease in patients with systemic sclerosis at the time of diagnosis, which may reduce unnecessary CT screening, according to data presented at ACR Convergence 2022.

News
November 07, 2022
3 min read
Save

Air pollution raises mortality risk, worsens lung function in fibrotic ILD

Air pollution raises mortality risk, worsens lung function in fibrotic ILD

In patients with fibrotic interstitial lung disease, exposure to small particulate matter was linked to increased mortality, poor lung function and faster disease progression, according to a study in JAMA Internal Medicine.

News
October 25, 2022
9 min read
Save

‘Time lost is lung lost’: Early diagnosis critical in pulmonary fibrosis

‘Time lost is lung lost’: Early diagnosis critical in pulmonary fibrosis

NASHVILLE, Tenn. — Delayed diagnosis of pulmonary fibrosis is an unfortunate reality for many patients, but experts are seeking to address this problem by closing knowledge gaps and increasing awareness of the disease.

News
October 24, 2022
2 min read
Save

Collaboration with pulmonology key to managing ILD in autoimmune disease

Collaboration with pulmonology key to managing ILD in autoimmune disease

SAN DIEGO — A clear intervention plan and collaboration with pulmonology are key to managing patients with interstitial lung disease in autoimmune conditions, according to a speaker at the Congress of Clinical Rheumatology West.

News
October 22, 2022
3 min read
Save

Future of systemic sclerosis treatment will likely be combination therapy

Future of systemic sclerosis treatment will likely be combination therapy

SAN DIEGO — Patients with systemic sclerosis will likely require multidisciplinary management with combination therapy to treat the myriad complications that may arise, according to a speaker at the Congress of Clinical Rheumatology West.

News
October 20, 2022
1 min read
Save

Cyclophosphamide treatment for systemic sclerosis linked to lower ovarian reserve in women

Cyclophosphamide treatment for systemic sclerosis linked to lower ovarian reserve in women

NASHVILLE, Tenn. — In women with systemic sclerosis, cyclophosphamide therapy negatively correlated with ovarian reserve, according to a presenter at the CHEST Annual Meeting.

News
October 17, 2022
2 min read
Save

Nintedanib maintains safety, efficacy long-term in patients with SSc-associated ILD

Nintedanib maintains safety, efficacy long-term in patients with SSc-associated ILD

Nintedanib maintains its safety and efficacy for up to 3 years in patients with systemic sclerosis-associated interstitial lung disease, according to data published the Annals of the Rheumatic Diseases.

News
October 16, 2022
3 min read
Save

Patients with ILD living in rural areas do not have worse outcomes, study finds

Patients with ILD living in rural areas do not have worse outcomes, study finds

NASHVILLE, Tenn. — People with interstitial lung disease living in rural areas do not appear to have greater risk for death, lung transplant, acute exacerbation or disease progression compared with those in urban areas, researchers reported.

News
October 05, 2022
1 min read
Save

Influenza vaccination shows mixed results on all-cause mortality in patients with ILD

Influenza vaccination shows mixed results on all-cause mortality in patients with ILD

Among patients with interstitial lung disease, those who received an influenza vaccination demonstrated a significant reduction in all-cause mortality in two of the four seasons evaluated in a recent study.

News
October 05, 2022
2 min read
Save

Higher-dose treprostinil yields greater improvements in pulmonary hypertension-ILD

Higher-dose treprostinil yields greater improvements in pulmonary hypertension-ILD

Patients with pulmonary hypertension associated with interstitial lung disease had better outcomes with a higher dose of inhaled treprostinil, as compared with a lower dose or placebo, according to a study.

View more